Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose crossover PK/PD comparison of SAR342434 vs Humalog in healthy Japanese males
jRCT2080225283Phase 1Completed
- Sponsor
- Sanofi
- Start
- Jul 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of insulin lispro (Wockhardt) in diabetes mellitus type 1 (T1D) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sanofi. Primary endpoints: Pharmacokinetic exposure of SAR342434 vs Humalog and Glucose-lowering activity via euglycemic clamp. Started Jul 2020; status: completed.
02
Drugs
insulin lispro (Wockhardt)
03
Conditions
diabetes mellitus type 1 (T1D)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2080225283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225283.